Insight Molecular Diagnostics Inc. · NASDAQ:IMDX
Insight Molecular Diagnostics — Oncocyte — Shareholder Meeting (June 2020)
23 slides from Insight Molecular Diagnostics's shareholder meeting presentation, Jun 17, 2020
Slide 1: Annual Shareholder's Meeting
Annual Shareholder’s Meeting ONCOCYTE LIVES Ron Andrews
Slide 2: Forward Looking Statement
Forward Looking Statement Oncocyte cautions you that this presentation contains forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and
Slide 3: Mission Statement
Mission Statement We are a molecular diagnostics company whose mission is to provide actionable answers to physicians and patients at critical decision points across the cancer care continuum, to optimize diagnosis and treatment, improve patient outcomes, and reduce overall cost of care. NON-CONFIDE
Slide 4: Investment Highlights
Investment Highlights Proprietary molecular diagnostic tests 2 DetermaRx™ improves patient survival, stratifies address key decision points along the (early-stage lung cancer patients to identify lung cancer treatment continuum to 60 those who may benefit from adjuvant improve patient outcomes. chem
Slide 5: Experienced Leadership Team
Experienced Leadership Team Pioneering Molecular Diagnostics RONALD ANDREWS — AL PARKER MITCH LEVINE PADMA SUNDAR LYNDAL DOUG ROSS, President & Chief Chief Operating Officer Chief Financial Officer Senior Vice President, HESTERBERG, PhD = MD PhD Executive Officer Commercial Chief Scientific Officer
Slide 6: Decision Points Along the Cancer Care Continuum
n Points Along the Cancer Care Continuum Diagnosis of Cancer Post-Diagnosis Does patient have Should | biopsy Should igive Should 1give Should igive _—isthetherapy —is the cancer lung cancer? the nodule? adjuvant chemo? targetedtherapy? immunotherapy? working coming back? Therapy Semis Treatment Tar
Slide 7: Decision Points Along the Cancer Care Continuum
Decision Points Along the Cancer Care Continuum Diagnosis of Cancer Post-Diagnosis Does patient have Should | biopsy Should | give Should give should give __—isthetherapy —is the cancer lung cancer? the nodule? adjuvant chemo? targetedtherapy? immunotherapy? working coming back? Therapy Targeted Tre
Slide 8: Oncocyte: Strategically Addressing Lung Cancer Decisions
Oncocyte: Strategically Addressing Lung Cancer Decisions Diagnosis of Cancer Genetic Pre-Disposition | Screening to determine if the patient has lung cancer Should 1 biopsy the nodule? DETERMAS” DIAGNOSIS n Develpent 8 NON-CONFIDENTIAL Post-Diagnosis of Cancer Should 1 give adjuvant chemo? DETERMAS’
Slide 9: We've Come A Long Way in Months
We've Come A Long Way in 12 Months Oncocyte has tremendous organizational velocity... ‘CORE Distribution Agreement Finalized i DetermaRx Received Final MolDx Coverage Decision 1 DetermaRx Early Access Launch DetermaRx MolDx Coverage Effective Close of Razor Genomics Acquisition i DetermalO CLIA Vali
Slide 10: Building a "One Lab Resource" for Lung Cancer
Building a “One Lab Resource” for Lung Cancer With overtwelve thousand call points intheU.S., anddecreasingefficiencyas _ Repsthat can only youmove down deciles, single product provide one clinical salesorganizationshitawallaround —_answercan struggleto 30-40% market penetration. get access to sampl
Slide 11: DetermaDx Update
DetermaDx Update Utilizing blood-based interrogation methods to leverage the immune system's response to cancer (ONCOCYTE
Slide 12: Lung Biopsies are Risky and Expensive
Lung Biopsies are Risky and Expensive aly 8 00090 Lin 4 invasive Mean U.S. cost of a biopsy is 96%: of nodules found through diagnostic procedures about $15,0002 screening are benign, whereas result in complications? —— Mean cost of biopsy with 24%-26% serious complications is greater of blapales re
Slide 13: Actionable Answers for a Critical Question in Lung Cancer Diagnosis
Actionable Answers for a Critical Question in Lung Cancer Diagnosis DetermaDx is a Non-Invasive Gene Expression Classifier with Binary Call >500,000 High-Risk Nodules* found annually DETERMAS’ ooo Liquid Biopsy Biomarkers Classifier Survellance Ukely Benign $1.75B 80) ) Market opportunity in U.S. al
Slide 14: DetermaDx Update
DetermaDX Update Clinical Validation remains on schedule for End of June completion Currently, data is being collected and synthesized by third party clinical trial “honest broker” for final data analysis OCX management is blinded with no access to results until third party work is complete and all
Slide 15: DetermaRx Update
DetermaRx Update Proprietary predictive test for early stage lung cancer (ONCOCYTE
Slide 16: Early-Stage Lung Cancer can be Deadly
Early-Stage Lung Cancer can be Deadly 40,000+ patients @ @ @ @ are diagnosed with early-stage non-squamous NSCLC in the U.S. annually! e eS e 3 0 a 5 0 of O of early-stage patients e e with NSCLC recur after surgical resection? Recurrence 0 due to presence of occult distant metastases despite ‘early
Slide 17: DetermaRx Can Help Save Lives!
DetermaRx Can Help Save Lives! Targets cytotoxic Stage IIIA chemotherapy only = to patients likely to ipshala agg benefit from treatment DETERMAS” + Ina published prospective study, DetermaRx demonstrated improvement in Intermediate. Jom 52% fees disease-free survival (DFS) when high-risk Risk patie
Slide 18: DetermaRx is Commercially Available
DETERMAS* is Commercially Available High-Risk * Patients BNABgreon 4 Protay Intermediate-Risk Resected, oa Pationts NSCLC FFPE ‘Sample Low-Risk Patients Algorithm Reimbursement Update + MolDx (CMS/Palmetto) coverage decision effective 06/14/2020. + CMS approval alone provides coverage for 70% of the
Slide 19: DetermaIO Update
DetermalIO Update Identifying Immunotherapy Responders (ONCOCYTE
Slide 20: Measuring the complete Tumor Micro-environment
Measuring the complete Tumor Micro-environment In a Recent Study DetermalIO Outperformed Current Tests Used To Select Patients Current Biomarkers fall short both clinically and Associated economically Fibroblasts n & ™ 800,000 patients eligible for 10 treatment/testing Stromal Physiology Determalo™
Slide 21: Key Milestones for 2H 2020
Key Milestones for 2H 2020 1H 2020 * Commercial team built-out and DetermaRx launched in Q1 ’20 + Final LCD DetermaRx received and billing commenced * DetermaRx clinical utility trial to begin enrollment * Completion of DetermaDx clinical validation *Close Pharma studies for DetermalO *IO TNBC data
Slide 22: Investment Highlights
Investment Highlights Proprietary molecular diagnostic tests 2 DetermaRx™ improves patient survival, stratifies address key decision points along the (early-stage lung cancer patients to identify lung cancer treatment continuum to 60 those who may benefit from adjuvant improve patient outcomes. chem
Slide 23: Thank You
Thank You SONCOCYTE